Targeting novel receptors in GBM

We have generated well-characterised monoclonal antibodies (mAbs) against two receptor proteins that are present on two discrete cell populations and propose to use these simultaneously to effectively target this devastating disease. By targeting two proteins specifically expressed on the tumour and not normal brain, we aim to reduce toxicity while effectively killing most of the tumour. We have conjugated the mAbs with a drug to make antibody drug conjugates (ADCs) and aim to test their killing efficacy in vitro.

To validate dual targeting using ADCs as an effective therapeutic strategy for GBM in vitro.

Validation of novel ADCs that have anti-cancer effects in primary GBM cell line models which would then serve as a base for further validation in animal models. This would pave the way for translation into the clinic to improve outcomes for patients with GBM.